Over the past year, trial data have emerged on therapeutic interventions in IgA nephropathy and lupus nephritis, including the effects of different doses of glucocorticoids and several novel targeted therapies. These data, in combination with the discovery of autoantibodies targeting nephrin in minimal change disease, can inform the management of immune-mediated glomerular diseases.
Key advances
-
A 6- to 9-month course of reduced-dose oral methylprednisolone is effective in lowering the risks of kidney failure in patients with IgA nephropathy and is associated with a lower risk of serious adverse effects compared with full-dose therapy3.
-
A 9-month treatment regimen with targeted-release budesonide, in addition to optimized supportive management, is well tolerated and can significantly reduce proteinuria and preserve eGFR in patients with IgA nephropathy at risk of disease progression6.
-
In active lupus nephritis, more patients had a complete clinical response when receiving an intensified anifrolumab regimen compared with placebo (difference not statistically significant); an intensified regimen might be required to achieve adequate serum anifrolumab levels8.
-
Most patients with lupus nephritis who discontinue maintenance immunosuppressive therapy after 2–3 years do not experience a relapse, and this observation supports the need to develop strategies to identify these patients at low risk of relapse9.
-
The discovery of anti-nephrin autoantibodies in a subset of patients with active non-congenital minimal change disease supports an autoimmune aetiology10.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rauen, T. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 373, 2225–2236 (2015).
Lv, J. et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. J. Am. Med. Assoc. 318, 432–442 (2017).
Lv, J. et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. J. Am. Med. Assoc. 327, 1888–1898 (2022).
Wheeler, D. C. et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 100, 215–224 (2021).
Fellström, B. C. et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389, 2117–2127 (2017).
Barratt, J. et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. https://doi.org/10.1016/j.kint.2022.09.017 (2022).
Mejia-Vilet, J. M., Malvar, A., Arazi, A. & Rovin, B. H. The lupus nephritis management renaissance. Kidney Int. 101, 242–255 (2022).
Jayne, D. et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann. Rheum. Dis. 81, 496–506 (2022).
Jourde-Chiche, N. et al. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Ann. Rheum. Dis. 81, 1420–1427 (2022).
Watts, A. J. B. et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J. Am. Soc. Nephrol. 33, 238–252 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.L. receives research support from Travere Therapeutics, Genentech, Omeros Corporation and the US NIH/NIAID, and reports consultancy agreements with ChemoCentryx, Travere Therapeutics, Aurinia Pharmaceuticals, Calliditas Therapeutics and GlaxoSmithKline. A.J. declares no competing interests.
Rights and permissions
About this article
Cite this article
Jalal, A., Li, T. The evolving landscape of immune-mediated glomerular diseases. Nat Rev Nephrol 19, 81–82 (2023). https://doi.org/10.1038/s41581-022-00666-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-022-00666-w